Menu
Back to Journals » International Journal of Nanomedicine » Volume 6
Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles
Authors Tian X, Lin X, Wei, Feng, Huang, Wang, Ren L, Diao
Published 23 February 2011 Volume 2011:6 Pages 445—452
DOI https://doi.org/10.2147/IJN.S16570
Review by Single anonymous peer review
Peer reviewer comments 3
Xin-Hua Tian1, Xiao-Ning Lin1, Feng Wei1, Wei Feng1, Zhi-Chun Huang1, Peng Wang1, Lei Ren2, Yi Diao1
1Department of Neurosurgery, Zhongshan Hospital of Xiamen University, Xiamen, People's Republic of China; 2Research Center of Biomedical Engineering, Xiamen, People's Republic of China
Background: Polybutylcyanoacrylate (PBCA) nanoparticles coated with polysorbate-80 have been extensively proposed for delivering drugs into the animal brain and have shown great potential for therapeutic applications. In this study, we made an attempt to deliver the chemotherapeutic drug, temozolomide, into the brain by using PBCA nanoparticles. The physicochemical characteristics, in vitro release, and brain targeting ability of the drug-loaded nanoparticles were investigated.
Results: Our results show that a significantly higher concentration of temozolomide in the form of polysorbate-80-coated PBCA nanoparticles was observed in the brain (P < 0.05) in comparison with the free drug.
Conclusion: This study indicates that polysorbate-80 coated PBCA nanoparticles could be a feasible carrier for temozolomide delivery to the brain. It is anticipated that the developed formulation may improve on targeted therapy for malignant brain tumors in the future.
Keywords: temozolomide, polybutylcyanoacrylate, nanoparticles, polysorbate-80, brain targeting
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.